Mesendo, stem cell combination for treatment of cardiovascular diseases

Mesendo is a combination of mesenchymal stem cells and endothelial progenitor cells, derived from mononuclear cells. The cells are both derived from the patient's bone marrow, and are expanded ex vivo before being returned to the patient. Mesendo is used for the treatment of coronary ischemia, amyotrophic lateral sclerosis, acute myocardial infarction and critical limb ischemia. Treatment of coronary ischemia with Mesendo was found to be safe and feasible, with no adverse events. Left ventrical ejection fraction improved, there was reduction in myocardial ischemia, improvements in quality of life and decreased nitroglycerin consumption.